Search results for "Combination"

showing 10 items of 1379 documents

Treatment of human brucellosis with rifampin plus minocycline

2003

In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocyc…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentMinocyclineRisk AssessmentDrug Administration SchedulePharmacotherapyRecurrenceInternal medicinemedicineHumansPharmacology (medical)ChildInfusions IntravenousAdverse effectAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologyChemotherapyDose-Response Relationship Drugbusiness.industryRetrospective cohort studyMinocyclineMiddle AgedBrucellaSurgeryTreatment OutcomeInfectious DiseasesItalyOncologyTolerabilityChild PreschoolbrucellosisDrug Therapy CombinationFemaleRifampinbusinessRifampicinFollow-Up Studiesmedicine.drug
researchProduct

Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey.

2004

SUMMARY. Nonorgan-specific autoantibodies (NOSA) are common in patients with chronic hepatitis C virus infection. It is unclear whether serological markers of autoimmunity segregate in a cohort of cases with more severe liver damage. We assessed the relationship between NOSA and demographic, biochemical and histological features in 502 subjects with anti-HCV positive, HCV-RNA positive, HBsAg negative chronic hepatitis consecutively referred to four Italian liver units. Percutaneous liver biopsy was performed in all subjects. A single pathologist scored the biopsies using histology activity index classification. The overall prevalence of positivity for any NOSA was 36.9%. Antinuclear antibod…

AdultMalemedicine.medical_specialtyAnti-nuclear antibodyAdolescentAutoimmunityInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsAutoimmunitySerologyLiver diseaseVirologyInternal medicinemedicineHumansAdverse effectAgedAutoantibodiesHepatologybiologybusiness.industryAutoantibodyInterferon-alphaHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsInfectious DiseasesItalyAntibodies AntinuclearImmunologyCohortbiology.proteinDrug Therapy CombinationFemaleAntibodybusinessJournal of viral hepatitis
researchProduct

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Res…

2010

Caspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary efficacy end point was complete or partial response at end of caspofungin treatment. Response at week 12, survival and safety were additional end points. Enrollment was stopped prematurely because of low accrual, with 42 enrolled and 24 eligible, giving the study a power of 85%. Transplant was from unrelated donors in 16 patients; acute or chronic GVHD was present in 15. In all, 12 patients were neut…

AdultMalemedicine.medical_specialtyAntifungal AgentsDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationAspergillosischemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultPharmacotherapyCaspofunginInternal medicineMedicineAspergillosisHumansTransplantation HomologousaspergillosiscaspofunginAdverse effectSurvival rateAgedallogeneicTransplantationbusiness.industryHematopoietic Stem Cell Transplantationhematopoietic SCTHematologyMiddle Agedmedicine.diseaseSurgeryCalcineurinTransplantationEuropeSurvival RateTreatment OutcomechemistryDrug Therapy CombinationFemaleCaspofunginbusinessBone marrow transplantation
researchProduct

Topical Voriconazole as Supplemental Treatment for Acanthamoeba Keratitis

2020

Purpose Voriconazole was shown to inhibit ergosterol synthesis in various acanthamoeba species. The purpose of this study was to evaluate the clinical outcome of treatment with supplemental topical voriconazole in patients with acanthamoeba keratitis (AK). Methods All patients who had been treated for AK with voriconazole 1% drops in conjunction with topical first-line antiacanthamoeba therapy composed of polyhexamethylene biguanide (PHMB) 0.02% and propamidine isethionate 0.1% (Brolene) between November 2014 and August 2017 at the Department of Ophthalmology, University Medical Center Mainz, were included. The main outcomes were treatment failure and recurrence rate. Secondary outcomes wer…

AdultMalemedicine.medical_specialtyAntifungal AgentsVisual acuitymedicine.drug_classAntiprotozoal AgentsVisual AcuityAcanthamoebaCorneaYoung Adult03 medical and health sciences0302 clinical medicinePharmacotherapymedicineAnimalsHumansIn patientEye Infections ParasiticAgedRetrospective StudiesAged 80 and overVoriconazoleDose-Response Relationship Drugbusiness.industryBiguanideRetrospective cohort studyMiddle AgedEye infectionmedicine.diseaseDermatologyBenzamidinesOphthalmologyAcanthamoeba KeratitisAcanthamoeba keratitis030221 ophthalmology & optometryDrug Therapy CombinationFemaleVoriconazoleOphthalmic Solutionsmedicine.symptombusiness030217 neurology & neurosurgeryFollow-Up Studiesmedicine.drugCornea
researchProduct

Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension

2004

The objective was to study factors related to the changes induced by antihypertensive treatment on oxidative status, antioxidant activities, and reactive oxygen species by-products in whole blood and mononuclear peripheral cells. Eighty-nine hypertensive patients (mean age 46 years, 46 men, average 24-h blood pressure 139/88 mm Hg, body mass index 29) were included. After 3 months of nonrandomized allocation to antihypertensive treatment (20 nonpharmacologic, 36 beta-blockers, 33 angiotensin receptor blocker), oxidized/reduced glutathione ratio and malondialdehyde were significantly reduced, and the activity of superoxide dismutase, catalase, and glutathione peroxidase was significantly inc…

AdultMalemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentAngiotensin-Converting Enzyme Inhibitorsmedicine.disease_causeBenzoatesAntioxidantsSuperoxide dismutasechemistry.chemical_compoundInternal medicineInternal MedicinemedicineHumansTelmisartanAntihypertensive AgentsWhole bloodchemistry.chemical_classificationReactive oxygen speciesbiologybusiness.industryGlutathione peroxidaseGlutathioneMiddle AgedMalondialdehydeOxidative StressHydrochlorothiazideTreatment OutcomeEndocrinologyAtenololchemistryHypertensionbiology.proteinBenzimidazolesDrug Therapy CombinationFemalebusinessOxidative stressDNA DamageAmerican Journal of Hypertension
researchProduct

Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports

2017

Abstract Rationale: To report our experience on 7 patients (4 males and 3 females), affected by nonparaneoplastic Lambert–Eaton myasthenic syndrome, treated with 3,4-diaminopyridine phosphate (3,4-DAPP) either alone or in combination with other immunosuppressants or steroids. Patient concerns: Patients have been evaluated at specific timepoints (ie, baseline and last 5 year follow-up), with neurological examination, autoantibodies against presynaptic voltage-gated Cav2.1 (P/Q type) calcium ion channel (VGCC) dosage, neurophysiological evaluation focusing on the increased amplitude of the compound muscle action potential (cMAP) after maximum voluntary effort, quantitative myasthenia gravis (…

AdultMalemedicine.medical_specialtyAzathioprineNeurological examination030204 cardiovascular system & hematologySeverity of Illness Index5300nonparaneoplastic-Lambert–Eaton myasthenic syndrome03 medical and health sciences0302 clinical medicinePrednisoneInternal medicineSeverity of illnessActivities of Daily LivingAzathioprinemedicineHumansMuscle StrengthClinical Case Report4-AminopyridineAdverse effect34-diaminopyridine phosphate; nonparaneoplastic-Lambert-Eaton myasthenic syndrome; 4-Aminopyridine; Activities of Daily Living; Adult; Azathioprine; Drug Therapy Combination; Female; Humans; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscle Strength; Prednisone; Severity of Illness Index; Treatment Outcome; Medicine (all)medicine.diagnostic_testbusiness.industry34-diaminopyridine phosphateGeneral MedicineMiddle Agedmedicine.diseaseMyasthenia gravisLambert-Eaton Myasthenic SyndromeTreatment OutcomeConcomitantPrednisoneDrug Therapy CombinationFemaleAmifampridinebusinessLambert-Eaton myasthenic syndrome030217 neurology & neurosurgeryImmunosuppressive Agentsmedicine.drugResearch Article
researchProduct

Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants

2018

Abstract Background Treatment-emergent affective switch (TEAS), including treatment-emergent mania (TEM), carry significant burden in the clinical management of bipolar depression, whereas the use of antidepressants raises both efficacy, safety and tolerability concerns. The present study assesses the prevalence and clinical correlates of TEM in selected sample of Bipolar Disorder (BD) Type-II (BD-II) acute depression outpatients. Methods Post-hoc analysis of the clinical and psychopathological features associated with TEM among 91 BD-II depressed outpatients exposed to antidepressants. Results Second-generation antipsychotics (SGA) (p = .005), lithium (≤ .001), cyclothymic/irritable/hypert…

AdultMalemedicine.medical_specialtyBipolar DisorderAdolescentLithium (medication)media_common.quotation_subjectTreatment-emergent-maniaAntidepressantGastroenterologyYoung Adult03 medical and health sciencesBipolar Disorder (BD) Antidepressant Depression Treatment-emergent-mania0302 clinical medicineInternal medicineRecall biasOutpatientsmedicineHumansBipolar disorderAgedmedia_commonAntidepressant; Bipolar Disorder (BD); Depression; Treatment-emergent-mania; Clinical Psychology; Psychiatry and Mental Healthbusiness.industryDepressionMiddle Agedmedicine.diseaseBipolar Disorder (BD)Antidepressive Agents030227 psychiatryClinical PsychologyCross-Sectional StudiesTreatment OutcomeTolerabilityPsychiatry and Mental HealthAntidepressantDrug Therapy CombinationFemaleTemperamentmedicine.symptombusinessMania030217 neurology & neurosurgeryAntipsychotic AgentsPsychopathologymedicine.drug
researchProduct

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observ…

2018

BACKGROUND: European guidelines recommend intravenous methylprednisolone as first-line treatment for active and severe Graves' orbitopathy; however, it is common for patients to have no response or have relapse after discontinuation of treatment. We aimed to compare the efficacy and safety of add-on mycophenolate to methylprednisolone in comparison with methylprednisolone alone in patients with moderate-to-severe Graves' orbitopathy.METHODS: MINGO was an observer-masked, multicentre, block-randomised, centre-stratified trial done in two centres in Germany and two in Italy. Patients with active moderate-to-severe Graves' orbitopathy were randomly assigned to receive intravenous methylprednis…

AdultMalemedicine.medical_specialtyCombination therapyAdolescentEndocrinology Diabetes and MetabolismPopulationMedizinAnti-Inflammatory Agents030209 endocrinology & metabolismMethylprednisoloneSeverity of Illness IndexMycophenolic acidlaw.inventionGraves' ophthalmopathy03 medical and health sciencesYoung Adult0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodlawInternal medicineJournal ArticleInternal MedicinemedicineHumanseducationAdverse effectAgededucation.field_of_studyAntibiotics Antineoplasticbusiness.industryMiddle AgedMycophenolic Acidmedicine.diseaseDiscontinuationGraves OphthalmopathyTreatment OutcomeMethylprednisoloneItaly030221 ophthalmology & optometryDrug Therapy CombinationFemalebusinessmedicine.drugThe lancet. Diabetesendocrinology
researchProduct

Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, gra…

1996

Differentiation induction therapy is being tested in myelodysplastic syndromes to ameliorate maturation defects and to restore normal hematopoietic function. To this end, 17 patients (eight with refractory anemia, two with refractory anemia and ring sideroblasts, and seven with refractory anemia and excess of blast cells) were treated with a combination of all-trans-retinoic acid (ATRA), granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), and alpha-tocopherol for durations of 8-16 weeks. Absolute neutrophil counts increased in all patients; platelet counts increased in five patients with discontinuation of transfusion needs in two of four transfusion-dependent patients. Sti…

AdultMalemedicine.medical_specialtyCombination therapyTretinoinBone Marrowhemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactorMedicineHumansVitamin EErythropoietinAgedAged 80 and overHematologybusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineMiddle Agedmedicine.diseaseGranulocyte colony-stimulating factorBlood Cell CountHematopoiesisHaematopoiesisEndocrinologymedicine.anatomical_structureErythropoietinMyelodysplastic SyndromesErythropoiesisDrug Therapy CombinationFemaleBone marrowbusinessmedicine.drugAnnals of hematology
researchProduct

Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF)

2019

BACKGROUND Hidradenitis suppurativa is a chronic inflammatory disease with high burden. Treatment options are often unsatisfactory. We assessed the effect of a combination therapy of intense pulsed light (IPL) and radiofrequency (RF). METHODS The explorative study included 47 patients and was performed as a prospective, monocentric, randomized, three-arm parallel-group design trial with a prior 12 weeks observation period. Treatment arms were IPL and RF monotherapies or IPL + RF combination therapy. After 12 weeks, all patients received IPL + RF for additional 12 weeks (cross-over). Primary endpoint was the change in active lesion numbers, secondary endpoint the change in Dermatology Qualit…

AdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentDermatologyIntense pulsed lightChronic inflammatory diseaseLesionYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCombined treatmentmedicineClinical endpointHumansHidradenitis suppurativaProspective Studies030203 arthritis & rheumatologybusiness.industryIntense Pulsed Light TherapyTreatment optionsMiddle AgedRadiofrequency Therapymedicine.diseaseCombined Modality TherapyDermatologyHidradenitis SuppurativaTreatment OutcomeQuality of LifeFemalesense organsmedicine.symptombusinessJournal of Dermatological Treatment
researchProduct